Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tazemetostat or placebo plus lenalidomide and rituximab in relapsed/refractory follicular lymphoma
CTR20220244Phase 3Terminated
- Sponsor
- Epizyme, Inc.
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in follicular lymphoma (FL) comparing TAZVERIK + lenalidomide + rituximab with Placebo + lenalidomide + rituximab (2 arms). Primary endpoint: Progression-free survival in ITT-WT and ITT-MT populations. Started Sep 2022; status: terminated.
02
Drugs
tazemetostat
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on CTR20220244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220244.